JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.

Binding assays were carried out under incubation conditions. JNJ-37822681 was tested at a concentration of 1 μM by CEREP (Celle L'Evescault, France) for its inhibition of radioligand binding to a battery of other neurotransmitter receptors, peptide receptors, and neurotransmitter transporters. JNJ-37822681 had a moderate binding affinity for the dopamine D2L receptor (Ki 158 nM), similar to olanzapine and clozapine. JNJ-37822681 displayed a weak affinity for the human dopamine D3 and serotonin 5-HT2A receptors and did not interact with the human receptors dopamine D1, adrenergic α1A, serotonin 5-HT2C, and histamine H1, up to the highest (10 μM) concentration tested. Further profiling at CEREP did not reveal any additional interactions except a high affinity to σ1 receptors (Ki 8.9 nM). Overall, JNJ-37822681 shows a high D2 specificity, especially compared with the second-generation antipsychotics that display a moderate to weak affinity for the D2 receptor, such as olanzapine, clozapine, and quetiapine.